Sunwin ( SUWN ) explodiert !

hallo, lebt hier noch jemand ?????

hier der artiklel


Da ist noch mehr drin!
Diese Empfehlung des maydornreports war ein echter Volltreffer. Trotz des bereits gewaltigen Kursanstiegs sehen die Autoren jedoch noch reichlich Kurspotenzial.

Anleger, die bereits bei der Erstempfehlung von Sunwin zugegriffen haben, können sich die Hände reiben: Das Papier lag bereits nach wenigen Wochen über 500 Prozent im Plus. Bislang hat das Team um Alfred Maydorn nur einen Teilgewinn realisiert. Zwar konsolidierte das Papier zuletzt, allerdings dürfte es nicht mehr lange dauern, bis sich das Papier wieder auf in Richtung Jahreshoch macht. Auf dem aktuellen Niveau beträgt das KGV lediglich 8. Der maydornreport sieht noch ein Kurspotenzial von 200 Prozent, das Kursziel lautet 2,30 Euro.

Behandelte Wertpapiere
SUNWIN INTL NEUTRA.DL-,01 (US8678771028; A0D9SL; S1N
 

 

da gebe ich dir recht.... aber ich glaube es erst wenn ich es sehen.......  

 

Dutton Associates Announces Investment Opinion: Sunwin International Neutraceuticals Strong Speculative Buy in Initiating Coverage by Dutton Associates

Monday , May 08, 2006 16:50 ET

EL DORADO HILLS, Calif., May 08, 2006 (BUSINESS WIRE) -- Dutton Associates initiates coverage of Sunwin International Neutraceuticals (OTCBB: SUWN) with a Strong Speculative Buy rating and a price target of $1.85. The 23-page report by Dutton senior analyst Stanley Ng is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

We are initiating coverage of Sunwin International Neutraceuticals, Inc. with a Strong Speculative Buy rating. The Company is principally engaged in the development, production and marketing of nutraceutical products, with a prime focus on calorie-free natural sweeteners, traditional Chinese medicine (TCM)-based veterinary medications and animal additives, and TCM-formula extracts for both human and animals. Most of these products are sold on a wholesale basis in the domestic market via a nationwide distribution network, as well as by exporting to overseas markets. In our opinion, the Company offers investors a good opportunity to invest in the huge and growing nutraceutical market, which comprises a wide variety of food and beverage products, dietary supplements and medications, as well as animal feeds and veterinary remedies. To strengthen its market position and to enhance its competitiveness, the Company is aggressively increasing its production capacity and marketing channels in North America for its stevioside, a calorie-free natural sweetener. Meanwhile, large capital expenditures to upgrade its production facilities to comply with the latest Good Manufacturing Practice (GMP) requirements introduced by the People's Republic of China (PRC) would enable it to capture greater market shares for its veterinary medicine and TCM products.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 29 senior analysts, primarily CFAs, have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 130 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. The Firm does not accept any equity compensation. We received $35,000 from the Company for 4 quarterly Research Reports with coverage commencing on 05/08/2006. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

SOURCE: Sunwin International Neutraceuticals

Dutton Associates
John M. Dutton, 916-941-8119

Copyright Business Wire 2006

 

das ist ja auch klasse...
also denkt mal nach!
ed  

ich glaube hier gibt es niemanden mehr der nachdenkt .... keiner mehr da. die mühe hier zu posten oder news/nachrichten einzustellen könnte man sich sparen.....  

Bin bei SUNWIN seit Höchststand drinnen. Was mich sehr wundert, ist dass kaum Reaktionen auf die guten News kommen. Technisch sieht es nicht schlecht aus, ein kleiner Aufwärtstrend zeigt sich, der aber sehr schwach ist.
Wahrscheinlich muss erst wieder ein großes Magazin positive News bringen, damit die Volumen nachziehen. Werde jedenfalls drinnen bleiben.  

http://www.jmdutton.com/research/suwn/reports/suwn_report_050806.pdf
In our opinion, the Company offers investors a good opportunity to invest in the huge and growing nutraceutical market,which comprises a wide variety of food and beverage products, dietary supplements and medications, as well as animalfeeds and veterinary remedies. To strengthen its market position and to enhance its competitiveness, the Company isaggressively increasing its production capacity and marketing channels in North America for its stevioside, a calorie-freenatural sweetener. Meanwhile, large capital expenditures to upgrade its production facilities to comply with the latest
Good Manufacturing Practice (GMP) requirements introduced by the People’s Republic of China (PRC) would enable it to capture greater market shares for its veterinary medicine and TCM products. Based on our earnings forecasts, the Company’s net profit for FY2006 is projected to grow 217.5% to $2.63 million, followed by an 84.5% rise to $4.86
million in FY2007 and a 51.4% increase to $7.35 million in FY2008. At a target price of $1.85, the stock would be trading at a prospective 25x estimated FY2007 earnings or 16.8x estimated FY2008 earnings. Investors should be aware that we have not fully factored in the likely earnings contribution from the North American market for its natural sweetener. Upcoming news flow is expected to be positive and help improve investor sentiment regarding the stock.

also Gewinnzunahme um 217% prophezeit auf $2,6 Millionen in 2006 und weiteren 84% in 2007 ohne Berücksichtigung des nordamerikanischen Marktes für Stevioside,den kalorienarmen Süsser  

 

Potential to market stevioside in the United States as a food supplement in the near term. This would be driven by the Company’s recent implementation of a comprehensive marketing plan to penetrate this multibilliondollar market, which would in turn open the doors in other western countries.

• Production capacity of stevioside is scheduled to increase sharply. This would be driven by the opening of a new 300-ton production plant in October 2006 at the newly acquired Science Park in Qufu and management’s current negotiation to acquire other stevioside manufacturers this year. Based on our projections, total production capacity would jump from 200 tons in FY2005 to 700 tons by the end of FY2007.

• Significant increase in sales of selected veterinary products. The recent pandemic of avian flu has triggered a sharp increase in demand for the Company’s hypericin and chlorine dioxide (ClO2). The former has been designated as a primary response to combat the avian flu virus, while the latter is an effective disinfectant recommended by the PRC Ministry of Agriculture for bird-flu prevention. Hypericin sales in February 2006
doubled the amount in November last year. new products in the market. An additional nine new medications are under development. The R&D partnership arrangement with major national and regional institutions and universities would ensure more new products could
be introduced to the market to drive revenue. Increasing awareness to cultivate safer and healthier livestock and poultry, as well as the need to prevent avian flu and other viruses worldwide, should drive demand for quality veterinary medicines.

• Organic growth and acquisition to drive the TCM business. Other than launching new TCM products through R&D and capacity expansion, the Company has recently registered 10 TCMs and four to five TCM-based health foods for sale in Canada. In addition, the Company is in negotiations to acquire a TCM company with annual revenue of RMB40–50 million. All of these factors will help drive growth.

• Strong financial position. The Company is in a strong financial position, with over $7 million of working capital and net cash of $3.6 million at January 31, 2006. No long-term debt was outstanding. Driven by its increasing earnings and strong cash flow from operations, we project the net-cash balance to increase from $3.5 million in
FY2006 to $5.4 million in FY2008. Accordingly, we see the need for issuing new common stock to fund capitalexpenditure and acquisition, which had caused significant EPS dilution in the past, diminishing.
........
For the first three quarters of FY2006, TCM and animal medicines continued to record steady growth in revenue, whilerevenue from stevioside gradually recovered as the impact of disruption on production due to reconstruction of the newmanufacturing facility was eased, following the commenced production of the facility in September 2005. Total revenueand net profit for the first nine months ending January 31, 2006 amounted to $11.07 million and $2.025 million. In the absence of any accounting adjustments, we expect the Company to record full-year revenue of $15.4 million and a net
profit of $2.63 million, representing a year-on-year increase of 27.2% and 217.5% respectively.
For the first nine months of FY2006 and the full year FY2005, gross margins for TCM were approximately 35%–40%,while those for veterinary medicines were approximately 30%–33%. Gross margin for stevioside was below 30% due to high raw-material costs. However, overall gross margins have been relatively stable at 28%–32%, even on a quarterly
basis. We believe the Company will maintain gross margins in excess of 30% in FY2007 and FY2008, as management has taken steps to ensure a stable supply of raw materials by increasing the prepayment to raw-material suppliers.
Looking ahead, we continue to expect robust growth in both revenue and net profit in FY2007 and FY2008.  

Cash Flow
Sunwin is expected to enjoy very strong cash flow from operating activities between FY2006 and FY2008. Even though management has budgeted more than $4 million on capital expenditure in each of FY2007 and FY2008, the liquidity requirements would be easily satisfied by strong cash flow from operating activities. In addition, management is expected to maintain its policy of using stock-based compensation in contracting professionals and consultants to help improve its operating structure and implementing a comprehensive marketing plan in North America.
In the past years, the Company relied on issuing new shares to fund its capital expenditures and asset acquisitions. The negative side of this policy is the significant dilution effect on EPS. As a matter of fact, the total number of common
shares has increased sharply from just 31 million at the end of FY2004 to 63.7 million by the end of FY2006. Weighted common shares rose from 17 million in FY2004 to nearly 50 million shares in FY2006. On the more positive side, management indicated that the Company would reduce its reliance on issuing new common shares to fund capital
expenditure or new asset acquisitions unless the size of an acquisition exceeds RMB80 million. This would reduce the negative impact of EPS dilution due to issuing a large number of new shares in the past years. For the time being, we believe the Company’s strong cash-flow position is sufficient to acquire the already-mentioned small-size stevioside manufacturer and a TCM manufacturer.  

Shanghai, China, May 10, 2006 (M2 PRESSWIRE via COMTEX) -- China Venture Forum, a leading equity research newsletter of micro- and small-cap China Stocks, announced China stocks to watch for Tuesday, May 9, 2006 include Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN) and China.com Inc. (NASDAQ: CHINA)SUWN trades about 22x earnings and 4.7x revenues.  

... jetzt sollte der Kurs sich doch mal wieder deutlicher bewegen.  

ist schon positiv ,dass er bei freerealtime vorbörslich grün angezeigt ist mit 2,5%  

bis jetzt tut sich nichts bei dem kurs. Ich denke es wird richtig spannend wenn die amis eröffnen, dann wird sich hier auch was bewegen und das nicht zu knapp.  

 

 

 

vom 15. bis 18. Mai auf der World Money Show in Las Vegas vertreten zu sein. Zu der Konferenz erwartet der Veranstalter über 8`800 Investoren und institutionelle Anleger. Auch diese Top-Empfehlung bleibt uneingeschränkt auf unserer Empfehlungsliste!

hab ich bei wallstreet online gelesen!

ich kann aber auf http://www.lasvegasmoneyshow.com/MS/lasVegas/main.asp nichts finden.

wisst ihr mehr darüber; bringt das was? wie wichtig ist sowas für sunwin  

in februar hat es auch solche events (Las Vegas Money Conferences) gegeben. meiner meinung nach bringen diese events nicht sehr viel. in februar hat es viel wirbel gegeben bei dieser aktie; dieser wirbel wurde aber nicht von den events ausgeloest.
ich bin zwischen anfang februar und ende maerz 5 mal hinein und hinaus gegangen (und jedes mal mit 6000 - 10000 aktien und gute gewinne) grundsatzlich stimmt die geschichte mit der stevia-pflanze und die chinesische medizin (alle produkte von Sunwin) schon.
Nur, ich bin derzeit eher nu beim beobachen, dass ich nicht sicher bin, ob wir derzeit schon die konsolidierung dieser aktie bzw. aktienmaerke, schon abgeschlossen haben
 

trotzdem waren die letzten tage enttäuschend. hab nicht gedacht das es runtergeht.
Am freitag die letzte Aktion von 1,18 auf 1,13 war nicht gerade toll.
ansonsten glaub ich weiter an die sache.

übrigens: ich war im reformhaus und hab mir stevia gekauft. steht drauf "für äußerliche anwendung"  

ein süsses nahrungsergänzungsmittel zur äußerlichen anwendung? das möchte ich sehen *lol*  

 

voll krass falsche Richtung ey was soll das !!!